Now that the Enbrel patent has issued, the question is what effect it will have on Enbrel FoB’s for the US market.
MRK’s Enbrel FoB being developed with Hanwha (#msg-64164954) is relying on the regular BLA pathway (according to MRK’s recent R&D Day webcast), but this does not obviate the need for MRK to have freedom from AMGN’s IP.
I had considered Enbrel and the other TNF-a drugs among the most attractive FoB compounds for MNTA (#msg-59857407), but the new patent changes this assessment with respect to Enbrel per se.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.